Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX20 in advanced solid tumors
NCT03588650Phase 1Completed
- Sponsor
- Henlius
- Start
- Aug 2018
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of opucolimab in solid tumor (advanced stage), sponsored by Henlius. Primary endpoint: Maximum tolerated dose of HLX20 at 1 year. Started Aug 2018; status: completed.
02
Drugs
opucolimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03588650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588650.